Aarti Drugs
Aarti Drugs Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Aarti Drugs targets 10%-15% volume growth over the next two years, driven by existing product capacity and new expansions (Page 12). Aarti Drugs expects sustained growth momentum driven by ongoing capacity expansion and operational excellence.
From Aarti Drugs's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Aarti Drugs targets 10%-15% volume growth over the next two years, driven by existing product capacity and new expansions (Page 12).
- Volume growth is expected even if the salicylic acid derivatives segment does not pick up immediately (Page 12).
- The Sayakha facility ramp-up will significantly increase captive consumption, supporting volume and margin growth (Page 13).
- Pricing pressures are expected to ease, potentially boosting demand and volume growth in upcoming quarters (Page 10).
- Focus on increasing sales in regulated markets (US, Europe) with new USFDA and CEP approvals is expected to expand higher-margin revenues (Page 12).
- Specialty chemical segment saw 149% growth and is expected to sustain or improve performance going forward (Page 8).
- Formulations segment growing steadily with exports constituting over 70% revenue, indicating growth potential in regulated markets (Page 5).
- Overall revenue growth of 19% YoY reported for Q1 FY27, driven by healthy realizations and volume increases (Page 5).
Profitability & Margins
See what Aarti Drugs said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company recently completed a capital expenditure of INR 600 crores focused on Phase 1 greenfield facilities, achieving an asset turnover of around 1.5x.
- Phase 2 brownfield capex is planned for Sayakha and G61 Tarapur sites, expected to deliver higher asset turnover of 3x to 4x due to existing infrastructure.
- Expansion underway at Baddi facility to nearly double oral solid dosage manufacturing capacity.
- Construction of additional USFDA-approved Metformin capacity (500+ tons/month) at Sarigam, expected to take 10-12 months to complete.
- Plans for a quasi greenfield USFDA plant adjacent to the current USFDA facility to more than double production capacity with 3 new multipurpose lines are underway.
- Sayakha facility will continue ramping up utilization to support growth, mainly through backward integration for antidiabetic portfolio.
- Continued investments aim to strengthen backward integration, manufacturing flexibility, and operational efficiency for sustainable growth.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Drugs said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Aarti Drugs — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹720 Cr, net profit ₹55 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Drugs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Aarti Drugs Q1 FY27 results?
Aarti Drugs targets 10%-15% volume growth over the next two years, driven by existing product capacity and new expansions (Page 12). Aarti Drugs expects sustained growth momentum driven by ongoing capacity expansion and operational excellence.
What is Aarti Drugs share price analysis?
Aarti Drugs currently shows a below-average growth signal. The stock trades at a P/E of 19.8 with a market cap of ₹3,810 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Drugs planning capital expenditure?
The company recently completed a capital expenditure of INR 600 crores focused on Phase 1 greenfield facilities, achieving an asset turnover of around 1.5x.
Keep Aarti Drugs on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.